Woodline Partners’s Arcturus Therapeutics ARCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-66,577
Closed -$408K 1031
2025
Q4
$408K Hold
66,577
﹤0.01% 923
2025
Q3
$1.23M Sell
66,577
-713,865
-91% -$11.5M 0.01% 786
2025
Q2
$10.2M Hold
780,442
0.05% 432
2025
Q1
$8.26M Sell
780,442
-26,470
-3% -$420K 0.05% 397
2024
Q4
$13.7M Buy
806,912
+26,956
+3% +$507K 0.09% 284
2024
Q3
$18.1M Buy
779,956
+25,933
+3% +$555K 0.15% 207
2024
Q2
$18.4M Sell
754,023
-160,341
-18% -$4.86M 0.18% 178
2024
Q1
$30.9M Sell
914,364
-155,450
-15% -$5.51M 0.28% 111
2023
Q4
$33.7M Hold
1,069,814
0.37% 76
2023
Q3
$27.3M Hold
1,069,814
0.32% 84
2023
Q2
$30.7M Buy
1,069,814
+251,376
+31% +$6.84M 0.36% 76
2023
Q1
$19.6M Buy
818,438
+66,107
+9% +$1.19M 0.27% 105
2022
Q4
$12.8M Sell
752,331
-125,193
-14% -$2.18M 0.17% 167
2022
Q3
$13M Buy
+877,524
New +$14.7M 0.18% 161
2021
Q2
Sell
-8,442
Closed -$349K 593
2021
Q1
$349K Buy
+8,442
New +$503K 0.01% 401
2020
Q4
Sell
-39,016
Closed -$1.67M 225
2020
Q3
$1.67M Sell
39,016
-109,067
-74% -$5.41M 0.05% 166
2020
Q2
$6.92M Buy
+148,083
New +$5.1M 0.27% 91

Other funds holding ARCT

Woodline Partners's ARCT Position: Q1 2026 in Review

Woodline Partners sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 66,577 shares — an estimated $408K sold.

Woodline Partners first reported a position in ARCT in Q2 2020 and held it in 17 quarters. The position peaked at $33.7M in Q4 2023. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Woodline Partners reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 66,577 Arcturus Therapeutics shares in Q1 2026, an estimated $408K.
  • Woodline Partners first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 17 quarters.
  • Woodline Partners's Arcturus Therapeutics position peaked at $33.7M in Q4 2023.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.